Prothena Announces Appointment of Chief Regulatory Officer
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Carol D. Karp as Chief Regulatory Officer. Ms. Karp will lead Prothena's Quality, Regulatory and Safety organizations.
This new position adds important expertise in line with Prothena's continued growth as a late-stage clinical biotechnology company with integrated research, development and commercial capabilities.
"Carol is a highly regarded leader who has successfully led global regulatory, quality and safety activities across multiple therapeutic areas and all stages of product development," said Gene Kinney, PhD, President and Chief Executive Officer of Prothena. "She joins Prothena as we are making steady advances across our pipeline and continue to prepare our commercial infrastructure in advance of key clinical data. We are delighted to have someone with Carol's expertise join our team to lead these key strategic activities."
Prior to joining Prothena, Ms. Karp was an independent regulatory consultant with an extensive and successful track record of leading global registration activities for innovative new products in the biotechnology and pharmaceutical sectors. Ms. Karp previously held executive leadership positions as Senior Vice President of Regulatory Affairs and Compliance at Esperion Therapeutics, and Vice President and Head of Global Regulatory Affairs, Pharmacovigilance & Risk Management at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company, where she led global regulatory affairs, regulatory operations and CMC regulatory for a portfolio of neurodegenerative product candidates. Prior to Janssen, Ms. Karp was Senior Vice President, Regulatory Affairs, Quality Assurance and Drug Safety at CV Therapeutics, which was acquired by Gilead Sciences. Ms. Karp also held senior regulatory and scientific affairs positions at PowderJect, VIVUS, Cygnus and Janssen Pharmaceutica.
Ms. Karp is a member of the Board of Trustees at the University of Rochester, and an expert advisor and member of the selection and review committees for the Stanford University School of Medicine's SPARK translational research program. Ms. Karp earned her BA in biology from the University of Rochester.
Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's website at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Ellen Rose 650-922-2405, firstname.lastname@example.org